Serum Neurotransmitter Analysis of Motor and Non-motor Symptoms in Parkinson's Patients

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2024 Dec 10

PMID 39654806

Authors

Yichun Fan

Wenping Yang

Weilan Wu

Xinjing Wang

Yuxin Lin

Linlin Wu

Jun Wang

Fei Huan

Haixia Ding

Rong Gao

Affiliations

Soon will be listed here.

Abstract

Clinical symptoms of Parkinson's disease (PD) are classified into motor and non-motor symptoms. Mental disorders, especially depression, are one of the major non-motor manifestations of PD. However, the underlying mechanisms remain poorly understood. In the present study, 21 neurotransmitters associated with mental disorders were measured in serum samples from patients and controls using the ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) assay. Additionally, five clinical scales-the MDS Unified Parkinson's Disease Rating Scale (UPDRS), the Non-Motor Symptoms Scale (NMSS), the Mini-Mental State Examination (MMSE), the Hamilton Anxiety Scale (HAMA), and the Hamilton Depression Scale (HAMD)-were used to evaluate the severity of both motor and non-motor symptoms in PD patients. Analysis of neurotransmitter metabolism revealed significant changes in the tryptophan (Trp) metabolic pathway in PD patients. Specifically, levels of Trp, kynurenine (KYN), kynurenic acid (KA), nicotinamide (NAM), and 5-methoxyltryptamine (MeOTA) were substantially decreased. Additionally, three other excitation/inhibiting amino acids-glutamic acid (Glu), 4-aminobutyric acid (GABA), and aspartic acid (Asp)-also declined. Moreover, neurotransmitter conversion ratios, such as KA/KYN, nicotinamide/niacin (NAM/NA), 5-hydroxytryptophan/tryptophan (5-HTP/Trp), and quinolinic acid/kynurenic acid (QA/KA), provided more dynamic insights into disrupted neurotransmitter metabolism. Correlation analyses between scale scores and neurotransmitter levels showed that concentrations of xanthurenic acid (XA) and the turnover rate of 3-hydroxykynurenine (3-HK) were negatively correlated with UPDRS scores, while 5-hydroxytryptamine (5-HT) and GABA levels were negatively correlated with non-motor symptoms in PD patients. In summary, this study elucidates, for the first time, the potential association and dynamics between altered neurotransmitter metabolism and the etiology of PD in terms of motor and non-motor functions. These findings offer novel biomarkers and therapeutic targets for the treatment of PD.

References

Liu X, Wang K, Deng X, Wei Y, Guo R, Liu S . Amelioration of olfactory dysfunction in a mouse model of Parkinson's disease via enhancing GABAergic signaling. Cell Biosci. 2023; 13(1):101. PMC: 10239587. DOI: 10.1186/s13578-023-01049-9. View

Edwards K, Zup S . Serotonin Pretreatment Abolishes Sex-specific NMDA-induced Seizure Behavior in Developing Rats. Neuroscience. 2021; 463:184-196. DOI: 10.1016/j.neuroscience.2021.03.033. View

Sorgdrager F, Vermeiren Y, van Faassen M, van der Ley C, Nollen E, Kema I . Age- and disease-specific changes of the kynurenine pathway in Parkinson's and Alzheimer's disease. J Neurochem. 2019; 151(5):656-668. PMC: 6899862. DOI: 10.1111/jnc.14843. View

Gerlach M, Gsell W, Kornhuber J, Jellinger K, Krieger V, Pantucek F . A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome. Brain Res. 1996; 741(1-2):142-52. DOI: 10.1016/s0006-8993(96)00915-8. View

Yuan Y, Zhou X, Tong Q, Zhang L, Zhang L, Qi Z . Change in plasma levels of amino acid neurotransmitters and its correlation with clinical heterogeneity in early Parkinson's disease patients. CNS Neurosci Ther. 2013; 19(11):889-96. PMC: 6493594. DOI: 10.1111/cns.12165. View

Titova N, Chaudhuri K . Non-motor Parkinson disease: new concepts and personalised management. Med J Aust. 2018; 208(9):404-409. DOI: 10.5694/mja17.00993. View

Dong L, An M, Gu H, Zhang L, Zhang J, Li C . PACAP/PAC1-R activation contributes to hyperalgesia in 6-OHDA-induced Parkinson's disease model rats via promoting excitatory synaptic transmission of spinal dorsal horn neurons. Acta Pharmacol Sin. 2023; 44(12):2418-2431. PMC: 10692161. DOI: 10.1038/s41401-023-01141-3. View

Armstrong M, Okun M . Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020; 323(6):548-560. DOI: 10.1001/jama.2019.22360. View

Lei S, Zavala-Flores L, Garcia-Garcia A, Nandakumar R, Huang Y, Madayiputhiya N . Alterations in energy/redox metabolism induced by mitochondrial and environmental toxins: a specific role for glucose-6-phosphate-dehydrogenase and the pentose phosphate pathway in paraquat toxicity. ACS Chem Biol. 2014; 9(9):2032-48. PMC: 4168797. DOI: 10.1021/cb400894a. View

10.

Brown S, Christofides K, Weissleder C, Huang X, Weickert C, Lim C . Sex- and suicide-specific alterations in the kynurenine pathway in the anterior cingulate cortex in major depression. Neuropsychopharmacology. 2023; 49(3):584-592. PMC: 10789861. DOI: 10.1038/s41386-023-01736-8. View

11.

Bai J, Zheng Y, Yu Y . Urinary kynurenine as a biomarker for Parkinson's disease. Neurol Sci. 2020; 42(2):697-703. DOI: 10.1007/s10072-020-04589-x. View

12.

Breasail M, Smith M, Tenison E, Henderson E, Lithander F . Parkinson's disease: the nutrition perspective. Proc Nutr Soc. 2022; 81(1):12-26. DOI: 10.1017/S0029665121003645. View

13.

Stocchi F, Antonini A, Barone P, Bellelli G, Fagiolini A, Strambi L . Exploring depression in Parkinson's disease: an Italian Delphi Consensus on phenomenology, diagnosis, and management. Neurol Sci. 2023; 44(9):3123-3131. PMC: 10415449. DOI: 10.1007/s10072-023-06740-w. View

14.

Gu Y, Zhang J, Zhao X, Nie W, Xu X, Liu M . Olfactory dysfunction and its related molecular mechanisms in Parkinson's disease. Neural Regen Res. 2023; 19(3):583-590. PMC: 10581567. DOI: 10.4103/1673-5374.380875. View

15.

Oz G, Terpstra M, Tkac I, Aia P, Lowary J, Tuite P . Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: detection of high GABA concentrations. Magn Reson Med. 2006; 55(2):296-301. DOI: 10.1002/mrm.20761. View

16.

Ali N, Alhamdan N, Al-Kuraishy H, Al-Gareeb A, Elekhnawy E, El-Saber Batiha G . Irisin/PGC-1α/FNDC5 pathway in Parkinson's disease: truth under the throes. Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(4):1985-1995. DOI: 10.1007/s00210-023-02726-9. View

17.

Qin W, Shi Y, Chen W, Jia X, Asakawa T . Can kynurenine pathway be considered as a next-generation therapeutic target for Parkinson's disease? An update information. Biosci Trends. 2022; 16(4):249-256. DOI: 10.5582/bst.2022.01352. View

18.

Mally J, Szalai G, Stone T . Changes in the concentration of amino acids in serum and cerebrospinal fluid of patients with Parkinson's disease. J Neurol Sci. 1997; 151(2):159-62. DOI: 10.1016/s0022-510x(97)00119-6. View

19.

Iwasaki Y, Ikeda K, Shiojima T, Kinoshita M . Increased plasma concentrations of aspartate, glutamate and glycine in Parkinson's disease. Neurosci Lett. 1992; 145(2):175-7. DOI: 10.1016/0304-3940(92)90015-y. View

20.

Shao Y, Li T, Liu Z, Wang X, Xu X, Li S . Comprehensive metabolic profiling of Parkinson's disease by liquid chromatography-mass spectrometry. Mol Neurodegener. 2021; 16(1):4. PMC: 7825156. DOI: 10.1186/s13024-021-00425-8. View